<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2225">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388514</url>
  </required_header>
  <id_info>
    <org_study_id>CIG: Z7C2CA5837</org_study_id>
    <nct_id>NCT04388514</nct_id>
  </id_info>
  <brief_title>Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure</brief_title>
  <acronym>CORMOR</acronym>
  <official_title>Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Sanitaria-Universitaria Integrata di Udine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondazione Toscana Gabriele Monasterio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Policlinico Militare, Roma - Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Liberatore di Atri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Umberto I di Torino</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università di Siena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Civile di Lucca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale di Siracusa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Sanitaria Locale di Vercelli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Sanitaria-Universitaria Integrata di Udine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim. The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute
      respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread worldwide. Beside the
      prescription of some promising drugs as chloroquine, azithromycin, antivirals
      (lopinavir/ritonavir, darunavir/cobicistat) and immunomodulating agents (steroids,
      tocilizumab), in our patients with mild to moderate pneumonia due to SARS-CoV-2 we planned a
      randomize study to evaluate, respect the best available therapy (BAT), the use of
      autohemotherapy treatement with an oxygen/ozone (O3) gaseous mixture as adjuvant therapy.

      Design. Multicentric, randomized study.

      Participants. Clinical presentations are based upon clinical phenotypes identified by the
      Italian Society of Emergency and Urgency Medicine (SIMEU - Società Italiana di Medicina di
      Emergenza-Urgenza) and patients that meet criteria of phenotypes 2 to 4 were treat with best
      available therapy (BAT), and randomized to receive or not O3-autohemotherapy.

      Main outcome measures. The end-point were the time of respiratory improvement and earlier
      weaning from oxygen support: these parameters were included in the SIMEU clinical phenotypes
      classification.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recruitment Details.

      The investigator enrolled, in the study, subjects with COVID-19 modest to moderate
      respiratory insufficiency (SIMEU clinical phenotypes 2-4) thus cared in an infectious disease
      ward.

      To note that The Italian Society of Emergency and Urgency Medicine (SIMEU - Società Italiana
      di Medicina di Emergenza-Urgenza) suggest to classified the COVID-19 patients in 5 clinical
      phenotypes:

        -  Phenotype 1: subjects with fever and without respiratory failure (normal Arterial Blood
           Gas analysis - ABG -, six-minute walking test - 6mWT - and Chest XR). These patients
           usually can manage at home maintaining quarantine period.

        -  Phenotype 2: subjects with fever but with ABG and/or Chest XR indicative of modest
           respiratory insufficiency (PO2&gt; 60 mmHg in ambient air) and / or pulmonary consolidation
           area. These patients need to be hospitalized because they can get quickly worse.

        -  Phenotype 3: subjects with fever associate to moderate-severe respiratory insufficiency
           (at triage PO2&lt; 60 mmHg in ambient air) and /or bilateral pulmonary consolidation area
           at Chest XR. These patients need to be treated with high flow oxygen therapy.

        -  Phenotype 4: subjects with respiratory failure with suspected ARDS (Adult Respiratory
           Distress Syndrome) or complicated pneumonia. These patients require hospitalization in
           sub-intensive care unit.

        -  Phenotype 5: subject with ARDS at the beginning. These patients will require Intensive
           Care Unit (ICU) admission and non-invasive positive pressure ventilation (NIPPV) or
           mechanical ventilation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 8, 2020</start_date>
  <completion_date type="Anticipated">October 8, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 8, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study includes 2 arms:
Arm A: Blood ozonization plus BAT (n= 45 subjects)
Arm B: Standard of Care only without Blood ozonization (n= 45 subjects)
To note that the Standard of Care are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Randomization, 1:1 ratio</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Time of respiratory improvement and earlier weaning from oxygen support</measure>
    <time_frame>3 days</time_frame>
    <description>Evaluation of ABG paramethers the day after the last blood ozonization procedure (Day 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The time of respiratory improvement and earlier weaning from oxygen support</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluation of ABG paramethers the one week after the last blood ozonization procedure (Day 10)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the length of hospitalization</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Asse the lenghth of hospital stay in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of the length of Intensive Care Unit (ICU) stay</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Asse the lenghth of ICU stay in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvment in chest imaging finding</measure>
    <time_frame>10 days</time_frame>
    <description>improving, worsening or stability of the chest imaging (chest CT, Chest XR and/or Point-of-Care Ultrasound) finding in the two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvment in cytokine release syndrome</measure>
    <time_frame>10 days</time_frame>
    <description>Evaluation of plasmatic cytochine (IL-6, lymphocyte typing for CD4, CD3, CD8, HLA-DR, CD45) response in the two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>SARS-CoV-2 Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Blood ozonization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood ozonization plus BAT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>BAT &quot;only&quot;
To note that the BAT are therapy with antiretroviral therapy (lopinavir/ritonavir 2 tablets every 12 hours or darunavir/cobicistat 1 tablet per day) and hidrossycloroquine 400 mg every 12 hours then first day, followed by 200 mg every 12 hours for other 4 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Medical Ozone procedure</intervention_name>
    <description>The systemic ozone treatment procedure was decided by the physician on duty and started preliminarily at the patient's bed with the drawing of autologous blood and, after proper O2/O3 mixing, with its re-infusion. After junction of an adequate venous patient's way with a dedicated latex free plastic bag containing 35 ml of sodium citrate, a blood amount of 200 ml is taken. At the end, the withdrawal line was washed and the re-infusion one was filled with saline solution. The blood, without any patient disconnection, was then mixed with a gas mixture of a 200 cc composed by 96% of Oxygen and 4% of Ozone with a therapeutic O3 range of 40 μg/mL of gas per mL of blood. In order to guarantee the O2/O3 homogeneous diffusion into the blood, the bag was gently mixed for about 10 minutes, therefore the blood was re-infused into the patients. The duration of ozone treatment lasted for 3 consecutive days.</description>
    <arm_group_label>Blood ozonization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and no pregnant female patients 18 years of age or older were eligible if they
             had a diagnostic specimen that was positive on RT-PCR, had pneumonia confirmed by
             chest imaging and gave their informed consent to participate at the study

        Exclusion Criteria:

          -  Exclusion criteria were pregnancy, G6PHD (glucose 6 phosphate dehydrogenase)
             deficiency, concomitant serious disease and failure to obtain informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amato De Monte</last_name>
    <role>Study Chair</role>
    <affiliation>Presidio Ospedaliero Universitario &quot;Santa Maria della Misericordia&quot;, Udine - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlo Tascini, MD</last_name>
    <phone>+39 0432 559355</phone>
    <email>c.tascini@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emanuela Sozio, MD</last_name>
    <phone>+39</phone>
    <email>emanuela.sozio@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dott. Amato De Monte</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amato De Monte, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://www.simeu.it/w/articoli/leggiArticolo/3964/leggi</url>
    <description>SIMEU Classification and Guidelines</description>
  </link>
  <link>
    <url>https://www.pagepressjournals.org/index.php/ozone/article/view/9014</url>
    <description>doi: 10.4081/ozone.2020.9014.</description>
  </link>
  <reference>
    <citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.</citation>
    <PMID>32187464</PMID>
  </reference>
  <reference>
    <citation>Elvis AM, Ekta JS. Ozone therapy: A clinical review. J Nat Sci Biol Med. 2011 Jan;2(1):66-70. doi: 10.4103/0976-9668.82319.</citation>
    <PMID>22470237</PMID>
  </reference>
  <reference>
    <citation>Bocci VA. Scientific and medical aspects of ozone therapy. State of the art. Arch Med Res. 2006 May;37(4):425-35. Review.</citation>
    <PMID>16624639</PMID>
  </reference>
  <reference>
    <citation>Smith NL, Wilson AL, Gandhi J, Vatsia S, Khan SA. Ozone therapy: an overview of pharmacodynamics, current research, and clinical utility. Med Gas Res. 2017 Oct 17;7(3):212-219. doi: 10.4103/2045-9912.215752. eCollection 2017 Jul-Sep. Review.</citation>
    <PMID>29152215</PMID>
  </reference>
  <reference>
    <citation>Gulmen S, Kurtoglu T, Meteoglu I, Kaya S, Okutan H. Ozone therapy as an adjunct to vancomycin enhances bacterial elimination in methicillin resistant Staphylococcus aureus mediastinitis. J Surg Res. 2013 Nov;185(1):64-9. doi: 10.1016/j.jss.2013.05.085. Epub 2013 Jun 19.</citation>
    <PMID>23809152</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Sanitaria-Universitaria Integrata di Udine</investigator_affiliation>
    <investigator_full_name>Carlo Tascini</investigator_full_name>
    <investigator_title>Infectious Diseases Department</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Respiratory Failure</keyword>
  <keyword>COVID-19</keyword>
  <keyword>medical ozone</keyword>
  <keyword>ozone therapy</keyword>
  <keyword>cytokine release syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
    <ipd_access_criteria>Contacting the Principal Investigator</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 8, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04388514/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

